By Dave Sebastian

Gilead Sciences Inc. and Galapagos NV said their arthritis drug got a scientific recommendation from the European Medicines Agency to grant marketing authorization in Europe.

The recommendation comes after phase 2 and 3 studies for the drug, Jyseleca, met primary endpoints, the companies said Friday.

The European Commission will now review the recommendation, with an expected decision in the third quarter, the companies said. If authorized, the company can market the drug in the European Union's 27 countries.

The companies said the once-daily filgotinib had a consistent clinical safety profile when applied as monotherapy or in combination with methotrexate during the trials.

Write to Dave Sebastian at dave.sebastian@wsj.com

(END) Dow Jones Newswires

July 24, 2020 08:59 ET (12:59 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Galapagos (EU:GLPG)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024 Plus de graphiques de la Bourse Galapagos
Galapagos (EU:GLPG)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024 Plus de graphiques de la Bourse Galapagos